COST OF BEST SUPPORTIVE CARE IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIATIC ARTHRITIS IN THE UNITED STATES

被引：0
|
作者：
Tencer, T. [1 ]
Li, S. [2 ]
Zhang, F. [1 ]
机构：
[1] Celgene Corp, Summit, NJ USA
[2] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.1129
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A222 / A222
页数：1
相关论文
共 50 条
  • [31] Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients With Comorbid Psoriatic Arthritis
    Feldman, Steven R.
    Zhao, Yang
    Shi, Lizheng
    Mary Helen Tran
    Lu, Jackie
    ARTHRITIS CARE & RESEARCH, 2015, 67 (05) : 708 - 717
  • [32] Cardiometabolic Abnormalities in Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis: The PRISTINE Trial
    Husni, M. Elaine
    Qureshi, Abrar A.
    Szumski, Annette
    Koenig, Andrew S.
    Robertson, Debbie H.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S191 - S191
  • [33] The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
    Avci, Ali Berkant
    Feist, Eugen
    Burmester, Gerd Rudiger
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [34] PATTERNS OF CARE IN THE PHARMACOLOGIC TREATMENT OF MODERATE-TO-SEVERE PSORIASIS
    Hankin, C. S.
    Lebwohl, M.
    Knispel, J.
    Dunn, J. D.
    Lopes, M.
    Bronstone, A.
    Wang, Z.
    VALUE IN HEALTH, 2009, 12 (03) : A139 - A139
  • [35] Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
    Papp, Kim
    Gottlieb, Alice B.
    Shuler, Catherine L.
    Burge, Russel T.
    Cameron, Gregory
    Kerr, Lisa
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [36] Effect of Distraction Arthroplasty in the Treatment of Moderate-to-Severe Ankle Arthritis
    Wang, Jian
    Wang, Chenhan
    Ding, Xiaoheng
    Dong, Quanyu
    ORTHOPAEDIC SURGERY, 2024, 16 (09) : 2167 - 2172
  • [37] Patterns of Systemic Treatment for Psoriatic Arthritis in the United States
    Lee, Moa P.
    Lii, Joyce
    Jin, Yinzhu
    Desai, Rishi J.
    Solomon, Daniel H.
    Merola, Joseph F.
    Kim, Seoyoung C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 326 - 327
  • [38] Above-Label Dosing with Biologics in Treatment-NaiVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
    Schwartzman, Sergio
    Li, Yunfeng
    Zhou, Huanxue
    Herrera, Vivian
    Palmer, Jacqueline B.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [39] TREATMENT OF MODERATE-TO-SEVERE ACTIVE PSORIATIC ARTHRITIS: COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ANALYSIS OF BIOLOGICS AND TARGETED THERAPIES APPROVED IN THE RUSSIAN FEDERATION
    Rudakova, A.
    Tolkacheva, D.
    Sokolova, V
    VALUE IN HEALTH, 2022, 25 (01) : S117 - S118
  • [40] Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
    Bernd Schweikert
    Chiara Malmberg
    Örjan Åkerborg
    Gayathri Kumar
    Debby Nott
    Sandeep Kiri
    Christophe Sapin
    Susanne Hartz
    PharmacoEconomics - Open, 2020, 4 : 635 - 648
12345